Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

Regina Toomey Bueno, former oncology admin at Garnet Health, had good insurance, lots of support, and 2 cancer diagnoses. She ...

March is Myeloma Awareness Month, a time to recognize the subtle but serious symptoms of multiple myeloma, including persistent fatigue, unexplained bone pain and anemia. Since diagnosis is often ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Our friend and colleague Kevin Drum passed away on March 7. He was 66 and had been living with multiple myeloma for 11 years, ...

People watching Davenport City Council meetings will now be able to view public commenters after the city council voted unanimously to stream that portion of the meeting again.

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...